BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 32023523)

  • 1. It's About Time!
    Tempero M
    J Natl Compr Canc Netw; 2020 Feb; 18(2):115. PubMed ID: 32023523
    [No Abstract]   [Full Text] [Related]  

  • 2. Overview: FDA Approval of Olaparib Maintenance for BRCA-Mutated.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Jul; 33(7):. PubMed ID: 31365755
    [No Abstract]   [Full Text] [Related]  

  • 3. PARP inhibitor receives FDA breakthrough therapy designation in castration resistant prostate cancer: beyond germline BRCA mutations.
    Helleday T
    Ann Oncol; 2016 May; 27(5):755-7. PubMed ID: 26865580
    [No Abstract]   [Full Text] [Related]  

  • 4. [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    Hilmi M; Neuzillet C
    Bull Cancer; 2020 Oct; 107(10):961-962. PubMed ID: 32943226
    [No Abstract]   [Full Text] [Related]  

  • 5. Talazoparib for BRCA-mutated advanced breast cancer.
    Gunjur A
    Lancet Oncol; 2018 Oct; 19(10):e511. PubMed ID: 30146245
    [No Abstract]   [Full Text] [Related]  

  • 6. Olaparib, a new hope for ovarian cancer.
    Samoon Z; Jabbar AA
    Indian J Cancer; 2020; 57(3):346-347. PubMed ID: 32675438
    [No Abstract]   [Full Text] [Related]  

  • 7. The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    Domchek SM
    Clin Adv Hematol Oncol; 2018 May; 16(5):330-332. PubMed ID: 29851928
    [No Abstract]   [Full Text] [Related]  

  • 8. Olaparib (Lynparza) for advanced ovarian cancer.
    Med Lett Drugs Ther; 2016 Feb; 58(1489):e32-3. PubMed ID: 26938702
    [No Abstract]   [Full Text] [Related]  

  • 9. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PARP inhibition in BRCA2-mutated prostate cancer.
    Nientiedt C; Tolstov Y; Volckmar AL; Endris V; Bonekamp D; Haberkorn U; Jäger D; Sültmann H; Stenzinger A; Hohenfellner M; Grüllich C; Duensing S
    Ann Oncol; 2017 Jan; 28(1):189-191. PubMed ID: 27687312
    [No Abstract]   [Full Text] [Related]  

  • 11. [Olaparib and pancreatic cancer: A challenging Lesson].
    Louvet C; Samalin E; Michel P
    Bull Cancer; 2019 Sep; 106(9):715-716. PubMed ID: 31399206
    [No Abstract]   [Full Text] [Related]  

  • 12. Durable response to olaparib in pancreatic duct adenocarcinoma with deleterious ARID1A mutation.
    Zhao XS; Zhou J; Dong L; Zhang H; Ye YJ
    Chin Med J (Engl); 2019 Dec; 132(24):3012-3014. PubMed ID: 31764178
    [No Abstract]   [Full Text] [Related]  

  • 13. Resurrected cancer drug faces regulators.
    Ledford H
    Nature; 2014 Jun; 510(7506):454. PubMed ID: 24965630
    [No Abstract]   [Full Text] [Related]  

  • 14. What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
    Liu JF; Matulonis UA
    Curr Oncol Rep; 2016 May; 18(5):29. PubMed ID: 26984416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy.
    Roger E; Gout J; Arnold F; Beutel AK; Müller M; Abaei A; Barth TFE; Rasche V; Seufferlein T; Perkhofer L; Kleger A
    Cells; 2020 Sep; 9(9):. PubMed ID: 32948057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Olaparib in germline-mutated metastatic breast cancer: implications of the OlympiAD trial.
    Armstrong AC; Clay V
    Future Oncol; 2019 Jul; 15(20):2327-2335. PubMed ID: 31304797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.
    Rafii S; Gourley C; Kumar R; Geuna E; Ern Ang J; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Molife LR; Gore ME; Kaye SB; Yap TA
    Oncotarget; 2017 Jul; 8(29):47154-47160. PubMed ID: 28454085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the molecular defect in BRCA-deficient tumors for cancer therapy.
    Venkitaraman AR
    Cancer Cell; 2009 Aug; 16(2):89-90. PubMed ID: 19647219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.